{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T20:45:22Z","timestamp":1781297122850,"version":"3.54.1"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,4]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Oral fluid (OF) is being developed as a specimen for the determination of drug intake as an alternative to serum and plasma. It is generally considered as an attractive specimen due to the noninvasive nature of the sampling procedure and the relation to the free fraction of drug in the blood. These features are of particular value in drug treatment of psychiatric disorders. To establish OF for the purpose of monitoring drug therapy, the relationship between concentrations in OF and serum\/plasma must be documented. This study explored one promising sampling device and comprised the following 10 drugs: aripiprazole, citalopram, duloxetine, escitalopram, mirtazapine, pipamperone, pregabalin, promethazine, quetiapine, and venlafaxine.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>For this purpose, 100 paired serum and OF samples were collected from patients undergoing pharmacotherapy and analyzed using a liquid chromatography\u2013tandem mass spectrometry method. A commercial method from Chromsystems for the determination of these drugs in plasma was used and was adapted for OF and ultrafiltrated (Centrifree device) serum.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>The ratio of each individual pair of samples was used to calculate a mean and SD value between OF and serum free and total concentrations. The OF concentration ratios to serum total fraction differed markedly between substances and differed from 10-fold lower to 8-fold higher. The ratios to serum free fractions were always higher. The relation between the OF and serum concentrations was also evaluated by regression analysis and determination of slopes and correlation coefficients. For all measured relations, there was a statistically significant relation between the OF and serum concentrations. The degree of drug protein binding was in agreement with literature. The aripiprazole, duloxetine, pipamperone, pregabalin, and promethazine concentrations in ultrafiltrated serum were not possible to measure because of low concentrations and nonspecific binding.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Despite a strong statistical correlation between OF and serum concentrations observed for most of the studied substances, it is still evident that OF concentrations cannot simply substitute serum\/plasma as therapeutic drug monitoring specimen, but rather be considered as a unique specimen. We believe that OF is a promising matrix especially for compliance testing in psychiatry settings. The Greiner Bio-One device used in this study provides a sampling procedure that offers advantages over the available alternatives.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000000493","type":"journal-article","created":{"date-parts":[[2018,3,11]],"date-time":"2018-03-11T23:27:19Z","timestamp":1520810839000},"page":"245-251","source":"Crossref","is-referenced-by-count":22,"title":["Potential of Oral Fluid as a Clinical Specimen for Compliance Monitoring of Psychopharmacotherapy"],"prefix":"10.1097","volume":"40","author":[{"given":"Jasna","family":"Neumann","sequence":"first","affiliation":[{"name":"MVZ Labor Dessau GmbH, Dessau-Rosslau; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olof","family":"Beck","sequence":"additional","affiliation":[{"name":"MVZ Labor Dessau GmbH, Dessau-Rosslau; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norbert","family":"Dahmen","sequence":"additional","affiliation":[{"name":"\u00d6kumenisches Hainich Klinikum GmbH, M\u00fchlhausen, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"B\u00f6ttcher","sequence":"additional","affiliation":[{"name":"MVZ Labor Dessau GmbH, Dessau-Rosslau; and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230928","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1055\/s-0031-1286287","article-title":"AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011","volume":"44","author":"Hiemke","year":"2011","journal-title":"Pharmacopsychiatry."},{"key":"R2-20230928","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1093\/clinchem\/23.2.157","article-title":"Use of saliva in therapeutic drug monitoring","volume":"23","author":"Horning","year":"1977","journal-title":"Clin Chem."},{"key":"R3-20230928","doi-asserted-by":"crossref","first-page":"637","DOI":"10.4155\/bio.09.23","article-title":"Current technologies and considerations for drug bioanalysis in oral fluid","volume":"1","author":"Gallardo","year":"2009","journal-title":"Bioanalysis."},{"key":"R4-20230928","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.forsciint.2015.06.027","article-title":"Detection of illicit drugs in oral fluid from drivers as biomarker for drugs in blood","volume":"256","author":"Gjerde","year":"2015","journal-title":"Forensic Sci Int."},{"key":"R5-20230928","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jpba.2008.05.024","article-title":"LC-MS\/MS method for the determination of nine antidepressants and some of their main metabolites in oral fluid and plasma. Study of correlation between venlafaxine concentrations in both matrices","volume":"48","author":"de Castro","year":"2008","journal-title":"J Pharm Biomed Anal."},{"key":"R6-20230928","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1590\/S1676-26492008000200003","article-title":"Therapeutic carbamsazepine (CBZ) and valproic acid (VPA) monitoring in children using saliva as a biological fluid","volume":"14","author":"Maldonado","year":"2008","journal-title":"J Epilepsy Clin Neurophysiol."},{"key":"R7-20230928","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1093\/jat\/34.9.590","article-title":"Comparison of zopiclone concentrations in oral fluid sampled with Intercept(\u00ae) oral specimen collection device and Statsure Saliva Sampler\u2122 and concentrations in blood","volume":"34","author":"Gjerde","year":"2010","journal-title":"J Anal Toxicol."},{"key":"R8-20230928","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.forsciint.2013.02.010","article-title":"LC-MS\/MS of some atypical antipsychotics in human plasma, serum, oral fluid and haemolysed whole blood","volume":"229","author":"Fisher","year":"2013","journal-title":"Forensic Sci Int."},{"key":"R9-20230928","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/FTD.0000000000000242","article-title":"Determination of common antipsychotics in quantisal-collected oral fluid by UHPLC-MS\/MS: method validation and applicability for therapeutic drug monitoring","volume":"38","author":"Patteet","year":"2016","journal-title":"Ther Drug Monit."},{"key":"R10-20230928","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1093\/jat\/bkv123","article-title":"Influence of sampling procedure on codeine concentrations in oral fluid","volume":"40","author":"Coucke","year":"2016","journal-title":"J Anal Toxicol."},{"key":"R11-20230928","first-page":"1","article-title":"Oral fluid in toxicology","volume":"3","author":"Rai","year":"2006","journal-title":"Internet J Toxicol."},{"key":"R12-20230928","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1093\/jat\/32.6.393","article-title":"Drug testing in oral fluid\u2014evaluation of sample collection devices","volume":"32","author":"Langel","year":"2008","journal-title":"J Anal Toxicol."},{"key":"R13-20230928","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.forsciint.2005.02.028","article-title":"Oral fluid collection: the neglected variable in oral fluid testing","volume":"150","author":"Crouch","year":"2005","journal-title":"Forensic Sci Int."},{"key":"R14-20230928","first-page":"171","article-title":"Application of saliva for drug monitoring. An in vivo model for transmembrane transport","volume":"34","author":"Haeckel","year":"1996","journal-title":"Eur J Clin Chem Clin Biochem."},{"key":"R15-20230928","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1046\/j.1365-2125.2000.00253.x","article-title":"Citalopram and demethylcitalopram in human milk: distribution, excretion and effects in beast fed infants","volume":"50","author":"Rampono","year":"2000","journal-title":"J Clin Pharmacol."},{"key":"R17-20230928","first-page":"245","article-title":"Pharmacokinetic study of tramadol and its three metabolites in plasma, saliva and urine","volume":"17","author":"Ardakani","year":"2009","journal-title":"DARU."},{"key":"R18-20230928","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1515\/CCLM.2008.044","article-title":"Evaluation of a novel standardized system for collection and quantification of oral fluid","volume":"46","author":"Raggam","year":"2008","journal-title":"Clin Chem Lab Med."},{"key":"R19-20230928","first-page":"488","article-title":"Oral fluid levels of nicotine and metabolites in smokers as a function of collection device","volume":"33","author":"B\u00f6ttcher","year":"2011","journal-title":"Ther Drug Monit."},{"key":"R20-20230928","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1196\/annals.1384.001","article-title":"The use of oral fluid for therapeutic drug management: clinical and forensic toxicology","volume":"1098","author":"Langman","year":"2007","journal-title":"Ann N Y Acad Sci."},{"key":"R21-20230928","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1097\/FTD.0b013e31827c11e7","article-title":"Therapeutic drug monitoring of antiepileptic drugs by use of saliva","volume":"35","author":"Patsalos","year":"2013","journal-title":"Ther Drug Monit."},{"key":"R22-20230928","doi-asserted-by":"crossref","first-page":"63","DOI":"10.36076\/ppj.2014\/17\/63","article-title":"Utility of oral fluid in compliance monitoring of opioid medications","volume":"17","author":"Conermann","year":"2014","journal-title":"Pain Physician."},{"key":"R23-20230928","doi-asserted-by":"crossref","first-page":"435","DOI":"10.5055\/jom.2015.0293","article-title":"Assessment of the use of oral fluid as a matrix for drug monitoring in patients undergoing treatment for opioid addiction","volume":"11","author":"Kunkel","year":"2015","journal-title":"J Opioid Manag."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00007691-201804000-00011","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T01:06:56Z","timestamp":1695863216000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007691-201804000-00011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000000493","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]}}}